Semin intervent Radiol 2015; 32(04): 445-454
DOI: 10.1055/s-0035-1564794
Clinical Corner
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options

Brian Erly
1   Case Western Reserve University School of Medicine, Cleveland, Ohio
,
William D. Carey
2   Department of Gastroenterology, Cleveland Clinic, Cleveland, Ohio
,
Baljendra Kapoor
3   Section of Interventional Radiology, Imaging Institute, Cleveland Clinic, Cleveland, Ohio
,
J. Mark McKinney
4   Department of Radiology, Mayo Clinic, Jacksonville, Florida
,
Mathew Tam
5   Department of Radiology, Southend University Hospital, Essex, United Kingdom
,
Weiping Wang
4   Department of Radiology, Mayo Clinic, Jacksonville, Florida
› Author Affiliations
Further Information

Publication History

Publication Date:
10 November 2015 (online)

Cirrhosis is a result of advanced liver disease and is characterized by fibrosis of liver tissue and conversion of normal architecture into regenerative nodules,[1] [2] leading to a loss of liver function. According to the Centers for Disease Control, cirrhotic liver disease is responsible for 15,000 deaths per year in the United States.[3] [4] Portal hypertension (defined as elevation of hepatic venous pressure gradient ≥ 5 mm Hg) is a hallmark of cirrhosis, which is the result of a complicated process of inflammation, necrosis, collagen deposition, and regenerating nodules in the liver parenchyma.[5] [6] Increased portal pressure ultimately reduces portal blood flow, leading to the release of vasodilators and blood pooling in the splanchnic circulation. This results in renal hypoperfusion, with consequent activation of the renal–angiotensin–aldosterone system and fluid retention.[7] Combined with decreased oncotic forces from hypoalbuminemia, fluid leakage from the splanchnic circulation begins to exceed the capacity of the lymphatic drainage system, and ascites, a characteristic complication of decompensated cirrhosis, develops.[5] [6] [7]

In extreme cases, the maladaptive vasodilatory response can lead to hepatorenal syndrome (HRS), a rapidly progressive form of acute renal failure that occurs in patients with cirrhosis and ascites in the absence of other causes of renal failure. It is characterized by a marked reduction in glomerular filtration rate (GFR) and renal plasma flow. The hallmark of HRS is intense renal vasoconstriction with predominant peripheral arterial vasodilation. Tubular function is preserved with the absence of proteinuria or histologic changes in the kidney. HRS exists on a spectrum with milder forms of acute kidney injury in patients with cirrhosis.[8] It has been estimated that approximately 40% of patients with cirrhosis and ascites will develop HRS within 5 years, and 50% of patients hospitalized for a complication of cirrhosis will develop renal impairment, generally within a few days of admission.[9] [10] The prognosis for HRS is poor, with a mortality rate as high as 80% within 2 weeks.[11]

 
  • References

  • 1 Crawford JM. Liver and biliary tract. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005: 877-938
  • 2 Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of Liver-Related Mortality in the United States [Internet]. Gastroenterology. 2013 [cited June 24, 2013];(0): Available at: http://www.sciencedirect.com/science/article/pii/S0016508513004988 . Accessed October 13, 2015
  • 3 Jepsen P, Vilstrup H, Andersen PK, Lash TL, Sørensen HT. Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study. Hepatology 2008; 48 (1) 214-220
  • 4 D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44 (1) 217-231
  • 5 Oliver JA, Verna EC. Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome. Kidney Int 2010; 77 (8) 669-680
  • 6 Moore CM, Van Thiel DH. Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol 2013; 5 (5) 251-263
  • 7 Wong F, O'Leary JG, Reddy KR , et al; North American Consortium for Study of End-Stage Liver Disease. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 2013; 145 (6) 1280-1288.e1
  • 8 Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J 2008; 84 (998) 662-670
  • 9 Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362 (9398) 1819-1827
  • 10 Olivera-Martinez M, Sayles H, Vivekanandan R, D' Souza S, Florescu MC. Hepatorenal syndrome: are we missing some prognostic factors?. Dig Dis Sci 2012; 57 (1) 210-214
  • 11 Thorington JM, Scimidt CF. A study of urinary output and blood-pressure changes resulting in experimental ascites. Am J Med Sci 1923; 165: 880-889
  • 12 Wong F, Nadim MK, Kellum JA , et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60 (5) 702-709
  • 13 Arroyo V, Ginès P, Gerbes AL , et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23 (1) 164-176
  • 14 Munoz SJ. The hepatorenal syndrome. Med Clin North Am 2008; 92 (4) 813-837 , viii–ix v iii–ix.
  • 15 Ruiz-del-Arbol L, Monescillo A, Arocena C , et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42 (2) 439-447
  • 16 Zardi EM, Abbate A, Zardi DM , et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010; 56 (7) 539-549
  • 17 Møller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int 2008; 2 (4) 416-428
  • 18 Ruiz-del-Arbol L, Urman J, Fernández J , et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38 (5) 1210-1218
  • 19 Fasolato S, Angeli P, Dallagnese L , et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45 (1) 223-229
  • 20 Albillos A, de la Hera A, González M , et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37 (1) 208-217
  • 21 Stadlbauer V, Wright GA, Banaji M , et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008; 134 (1) 111-119
  • 22 Møller S, Iversen JS, Henriksen JH, Bendtsen F. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am J Physiol Heart Circ Physiol 2007; 292 (6) H2966-H2972
  • 23 Møller S, Henriksen JH. Review article: pathogenesis and pathophysiology of hepatorenal syndrome—is there scope for prevention?. Aliment Pharmacol Ther 2004; 20 (Suppl. 03) 31-41 , discussion 42–43
  • 24 Ginès P, Guevara M, Perez-Villa F. Management of hepatorenal syndrome: another piece of the puzzle. Hepatology 2004; 40 (1) 16-18
  • 25 Iwatsuki S, Popovtzer MM, Corman JL , et al. Recovery from “hepatorenal syndrome” after orthotopic liver transplantation. N Engl J Med 1973; 289 (22) 1155-1159
  • 26 Epstein M, Berk DP, Hollenberg NK , et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 1970; 49 (2) 175-185
  • 27 Koyama S, Kanai K, Aibiki M, Fujita T. Reflex increase in renal nerve activity during acutely altered portal venous pressure. J Auton Nerv Syst 1988; 23 (1) 55-62
  • 28 Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?. Gut 1997; 40 (5) 664-670
  • 29 Solis-Herruzo JA, Duran A, Favela V , et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 1987; 5 (2) 167-173
  • 30 Mohmand H, Goldfarb S. Renal dysfunction associated with intra-abdominal hypertension and the abdominal compartment syndrome. J Am Soc Nephrol 2011; 22 (4) 615-621
  • 31 de Laet IE, Malbrain M. Current insights in intra-abdominal hypertension and abdominal compartment syndrome. Med Intensiva 2007; 31 (2) 88-99
  • 32 Chok KS, Fung JY, Chan SC , et al. Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl 2012; 18 (7) 779-785
  • 33 Hasper D, Jörres A. New insights into the management of hepato-renal syndrome. Liver Int 2011; 31 (Suppl. 03) 27-30
  • 34 Leung W, Wong F. Hepatorenal syndrome: do the vasoconstrictors work?. Gastroenterol Clin North Am 2011; 40 (3) 581-598
  • 35 Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51 (2) 576-584
  • 36 Memon I, Klein CL. Impact of hepatorenal syndrome and liver transplantation. Curr Opin Organ Transplant 2011; 16 (3) 301-305
  • 37 Sharman A, Low J. Vasopressin and its role in critical care. Continuing education in anaesthesia. Crit Care Pain 2008; 8: 134-137
  • 38 Guevara M, Ginès P, Fernández-Esparrach G , et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27 (1) 35-41
  • 39 Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30 (4) 870-875
  • 40 Saló J, Ginès A, Quer JC , et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996; 25 (6) 916-923
  • 41 Krag A, Borup T, Møller S, Bendtsen F. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther 2008; 25 (11) 1105-1140
  • 42 Newswire PR. FDA Grants Orphan-Drug Designation for Novel Terlipressin Formulation for the Treatment of Ascites. [updated 2013 Jan 4, cited 2013 Jun 23] Available at: http://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-for-novel-terlipressin-formulation-for-the-treatment-of-ascites-185655002.html . Accessed October 13, 2015
  • 43 Nazar A, Pereira GH, Guevara M , et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010; 51 (1) 219-226
  • 44 Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002; 14 (12) 1363-1368
  • 45 Narahara Y, Kanazawa H, Sakamoto C , et al. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. J Gastroenterol 2012; 47 (3) 313-320
  • 46 Sanyal AJ, Boyer T, Garcia-Tsao G , et al; Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134 (5) 1360-1368
  • 47 Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25 (5) 880-885
  • 48 Alessandria C, Ottobrelli A, Debernardi-Venon W , et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47 (4) 499-505
  • 49 Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008; 103 (7) 1689-1697
  • 50 Duvoux C, Zanditenas D, Hézode C , et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36 (2) 374-380
  • 51 Karwa R, Woodis CB. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother 2009; 43 (4) 692-699
  • 52 Wong F, Moore K, Dingemanse J, Jalan R. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology 2008; 47 (1) 160-168
  • 53 Bennett WM, Keeffe E, Melnyk C, Mahler D, Rösch J, Porter GA. Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 1975; 135 (7) 964-971
  • 54 Hadengue A, Moreau R, Bacq Y, Gaudin C, Braillon A, Lebrec D. Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study. Hepatology 1991; 13 (1) 111-116
  • 55 Capella GL. Anti-leukotriene drugs in the prevention and treatment of hepatorenal syndrome. Prostaglandins Leukot Essent Fatty Acids 2003; 68 (4) 263-265
  • 56 Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Büttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 1995; 17 (2) 135-146
  • 57 Witzke O, Baumann M, Patschan D , et al. Which patients benefit from hemodialysis therapy in hepatorenal syndrome?. J Gastroenterol Hepatol 2004; 19 (12) 1369-1373
  • 58 Mitzner SR, Stange J, Klammt S , et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6 (3) 277-286
  • 59 Busk TM, Bendtsen F, Møller S. Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis. Eur J Gastroenterol Hepatol 2013; 25 (5) 523-530
  • 60 Rajekar H, Chawla Y. Terlipressin in hepatorenal syndrome: evidence for present indications. J Gastroenterol Hepatol 2011; 26 (Suppl. 01) 109-114
  • 61 Guevara M, Ginès P, Bandi JC , et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28 (2) 416-422
  • 62 Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study. Hepatology 1994; 19 (1) 129-132
  • 63 Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology 1999; 29 (3) 632-639
  • 64 Saugel B, Phillip V, Gaa J , et al. Advanced hemodynamic monitoring before and after transjugular intrahepatic portosystemic shunt: implications for selection of patients—a prospective study. Radiology 2012; 262 (1) 343-352
  • 65 Anderson CL, Saad WE, Kalagher SD , et al. Effect of transjugular intrahepatic portosystemic shunt placement on renal function: a 7-year, single-center experience. J Vasc Interv Radiol 2010; 21 (9) 1370-1376
  • 66 Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010; 59 (7) 988-1000
  • 67 Jalan R, Redhead DN, Thomas HW , et al. Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS). Eur J Gastroenterol Hepatol 1996; 8 (11) 1111-1116
  • 68 Gerbes AL, Gülberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998; 28 (3) 683-688
  • 69 Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 1995; 122 (11) 816-822
  • 70 Quiroga J, Sangro B, Núñez M , et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 1995; 21 (4) 986-994
  • 71 Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40 (1) 55-64
  • 72 Linas SL, Schaefer JW, Moore EE, Good Jr JT, Giansiracusa R. Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int 1986; 30 (5) 736-740
  • 73 Martin LG. Percutaneous placement and management of the Denver shunt for portal hypertensive ascites. AJR Am J Roentgenol 2012; 199 (4) 449-453
  • 74 Teperman L. Living donation for the very ill patient with type I hepatorenal syndrome: are we ready?. Liver Transpl 2012; 18 (7) 753-754
  • 75 Demirbas BT, Piskin T, Dayangac M , et al. Successful treatment of severe hepatorenal syndrome with living donor liver transplantation. Hepatogastroenterology 2012; 59 (119) 2305-2306
  • 76 Lee JP, Kwon HY, Park JI , et al. Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation. Liver Transpl 2012; 18 (10) 1237-1244
  • 77 Boyer TD, Sanyal AJ, Garcia-Tsao G , et al; Terlipressin Study Group. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 2011; 17 (11) 1328-1332
  • 78 Nadim MK, Kellum JA, Davenport A , et al; ADQI Workgroup. Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2012; 16 (1) R23
  • 79 Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant 2008; 8 (11) 2243-2251
  • 80 Ruiz R, Barri YM, Jennings LW , et al. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl 2007; 13 (6) 838-843
  • 81 Runyon BA ; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49 (6) 2087-2107
  • 82 Boyer TD, Haskal ZJ ; American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009. Hepatology 2010; 51 (1) 306
  • 83 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53 (3) 397-417
  • 84 Sharawey MA, Shawky EM, Ali LH, Mohammed AA, Hassan HA, Fouad YM. Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. Hepatol Int 2011; 5 (4) 927-933
  • 85 Seo YS, Jung ES, An H , et al. Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int 2009; 29 (10) 1521-1527
  • 86 Davenport A, Cholongitas E, Xirouchakis E, Burroughs AK. Pitfalls in assessing renal function in patients with cirrhosis—potential inequity for access to treatment of hepatorenal failure and liver transplantation. Nephrol Dial Transplant 2011; 26 (9) 2735-2742
  • 87 Verna EC, Brown RS, Farrand E , et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012; 57 (9) 2362-2370
  • 88 Londoño MC, Cárdenas A, Guevara M , et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007; 56 (9) 1283-1290
  • 89 Fidelman N, Kwan SW, LaBerge JM, Gordon RL, Ring EJ, Kerlan Jr RK. The transjugular intrahepatic portosystemic shunt: an update. AJR Am J Roentgenol 2012; 199 (4) 746-755
  • 90 Nazal L, Cárdenas A. Prognostic markers in patients with ascites and hepatorenal syndrome. Dis Markers 2011; 31 (3) 139-146
  • 91 Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. Dig Dis Sci 2011; 56 (4) 977-987
  • 92 Acevedo J, Fernández J, Prado V , et al. Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology 2013; 58 (5) 1757-1765
  • 93 McCormick PA, Donnelly C. Management of hepatorenal syndrome. Pharmacol Ther 2008; 119 (1) 1-6
  • 94 Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 2001; 34 (6) 1242-1251
  • 95 Fernández J, Navasa M, Planas R , et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133 (3) 818-824
  • 96 Tyagi P, Sharma P, Sharma BC, Puri AS, Kumar A, Sarin SK. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. Eur J Gastroenterol Hepatol 2011; 23 (3) 210-217